Bill Miller
Miller Value Partners
Bill Miller PACIRA THERAPEUTIC INC stake
total: 460
Miller Value Partners FLXN trades
- Total transactions:
- 17
- New positions:
- 1
- Sold out:
- 1
- Added:
- 9
- Reduced:
- 6
- Held since:
- 2017 Q2
- Held for:
- 16 quarters
- Latest activity:
- 2021 Q2
According to 2026 Q1 report, Bill Miller doesn't hold any PACIRA THERAPEUTIC INC (FLXN) shares. To date, the estimated cost basis is nearly $17.66 for "buy" trades and estimated average "sell" price is $9.88. Miller Value Partners first purchased FLXN in 2017 Q2, initially acquiring 527,800 shares. Since the initial investment in PACIRA THERAPEUTIC INC (FLXN), Miller Value Partners has made 16 more transactions.
When did Bill Miller sell PACIRA THERAPEUTIC INC (FLXN)?
Bill Miller sold off the entire PACIRA THERAPEUTIC INC (FLXN) position in 2021 Q2.
When did Bill Miller buy PACIRA THERAPEUTIC INC (FLXN)?
Bill Miller first invested in PACIRA THERAPEUTIC INC (FLXN) in 2017 Q2 at the reported quarter-end price of $20.22 per share.
What's the cost basis of Miller Value Partners's FLXN stake?
The estimated cost basis for PACIRA THERAPEUTIC INC (FLXN) stake is around $17.66 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $17.66
- Weighted AVG sell price:
- $9.88
Bill Miller's historical trades in PACIRA THERAPEUTIC INC
17 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q2
|
0.00%
|
0
|
$8.95
|
|
-100% (-4,101,735)
|
-1.04%
|
|
2021 Q1
|
1.04%
|
4,101,735
|
$8.95
|
$36,711,000
|
-2.25% (-94,365)
|
-0.03%
|
|
2020 Q4
|
1.64%
|
$11.54
|
-20.44% (-1,078,339)
|
|||
|
2020 Q3
|
2.17%
|
$10.41
|
+1.52% (+78,889)
|
|||
|
2020 Q2
|
3.03%
|
$13.15
|
+22.55% (+956,081)
|
|||
|
2020 Q1
|
2.15%
|
$7.87
|
-14.06% (-693,406)
|
|||
|
2019 Q4
|
3.65%
|
$20.70
|
-5.42% (-282,935)
|
|||
|
2019 Q3
|
2.89%
|
$13.71
|
+7.49% (+363,350)
|
|||
|
2019 Q2
|
2.38%
|
$12.30
|
+18.07% (+742,740)
|
|||
|
2019 Q1
|
2.04%
|
$12.48
|
+32.00% (+996,330)
|
|||
|
2018 Q4
|
1.61%
|
$11.32
|
+8.06% (+232,190)
|
|||
|
2018 Q3
|
1.76%
|
$18.71
|
+8.57% (+227,425)
|
|||
|
2018 Q2
|
2.58%
|
$25.85
|
-0.60% (-16,125)
|
|||
|
2018 Q1
|
2.56%
|
$22.41
|
-0.54% (-14,600)
|
|||
|
2017 Q4
|
2.91%
|
$25.04
|
+127.24% (+1,503,175)
|
|||
|
2017 Q3
|
1.31%
|
$24.18
|
+123.82% (+653,525)
|
|||
|
2017 Q2
|
0.49%
|
$20.22
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.